DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,887,618 | +7.7% | 11,639 | +4.2% | 0.14% | +7.4% |
Q2 2023 | $2,680,976 | -2.7% | 11,171 | +2.2% | 0.14% | -9.4% |
Q1 2023 | $2,756,083 | +129.1% | 10,935 | +141.2% | 0.15% | +106.9% |
Q4 2022 | $1,203,163 | -1.7% | 4,533 | -4.3% | 0.07% | -6.5% |
Q3 2022 | $1,224,000 | -0.2% | 4,737 | -2.1% | 0.08% | -4.9% |
Q2 2022 | $1,227,000 | -5.2% | 4,839 | +9.7% | 0.08% | +22.7% |
Q1 2022 | $1,294,000 | -2.7% | 4,413 | +9.2% | 0.07% | -1.5% |
Q4 2021 | $1,330,000 | +9.5% | 4,042 | +1.3% | 0.07% | -4.3% |
Q3 2021 | $1,215,000 | +3.8% | 3,991 | -8.6% | 0.07% | +6.1% |
Q2 2021 | $1,171,000 | +19.7% | 4,366 | +0.4% | 0.07% | +10.0% |
Q1 2021 | $978,000 | -3.2% | 4,348 | -4.4% | 0.06% | -13.0% |
Q4 2020 | $1,010,000 | -9.0% | 4,549 | -11.8% | 0.07% | -18.8% |
Q3 2020 | $1,110,000 | +2.8% | 5,159 | -15.5% | 0.08% | -4.5% |
Q2 2020 | $1,080,000 | +19.6% | 6,105 | -6.5% | 0.09% | -17.6% |
Q1 2020 | $903,000 | -17.5% | 6,530 | -8.5% | 0.11% | +36.7% |
Q4 2019 | $1,095,000 | +6.2% | 7,140 | 0.0% | 0.08% | -3.7% |
Q3 2019 | $1,031,000 | +1.5% | 7,140 | +0.4% | 0.08% | 0.0% |
Q2 2019 | $1,016,000 | +8.3% | 7,109 | 0.0% | 0.08% | +6.5% |
Q1 2019 | $938,000 | -18.0% | 7,109 | -35.9% | 0.08% | -31.9% |
Q4 2018 | $1,144,000 | – | 11,094 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |